Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
Authors: Durán Carlos E. , Riera-Arnau Judit , Abtahi Shahab , Pajouheshnia Romin , Hoxhaj Vjola , Gamba Magdalena , Alsina Ema , Martin-Perez Mar , Garcia-Poza Patricia , Llorente-Garcia Ana , Gonzalez-Bermejo Diana , Ibánez Luisa , Sabaté Mònica , Vidal Xavier , Ballarín Elena , Sanfélix-Gimeno Gabriel , Rodríguez-Bernal Clara , Peiró Salvador , García-Sempere Aníbal , Sanchez-Saez Francisco , Ientile Valentina , Ingrasciotta Ylenia , Guarneri Claudio , Tanaglia Matilde , Tari Michele , Herings Ron , Houben Eline , Swart-Polinder Karin , Holthuis Emily , Huerta Consuelo , Gini Rosa , Roberto Giuseppe , Bartolini Claudia , Paoletti Olga , Limoncella Giorgio , Girardi Anna , Hyeraci Giulia , Andersen Morten , Kristiansen Sarah Brøgger , Hallgreen Christine Erikstrup , Klungel Olaf , Sturkenboom Miriam 
Published: August 2023

Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women.

Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription.

Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12–55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy. Monthly utilisation figures (incidence rates [IR], prevalence rates [PR] and proportions) of oral retinoids were calculated, as well as discontinuation rates, contraception coverage, pregnancy testing, and rates of exposed pregnancies to oral retinoids, before and after the 2018 RMMs.

Results: From 10,714,182 females of child-bearing age, 88,992 used an oral retinoid at any point during the study period (mean age 18.9–22.2 years old). We found non-significant level and trend changes in incidence or prevalence of retinoid use in females of child-bearing age after the 2018 RMMs. The reason of discontinuation was unknown in &gt;95% of cases. Contraception use showed a significant increase trend in Spain; for other databases this information was limited. Pregnancy testing was hardly recorded thus was not possible to model ITS analyses. After the 2018 RMM, rates of pregnancy occurrence during retinoid use, and start of a retinoid during a pregnancy varied from 0.0 to 0.4, and from 0.2 to 0.8, respectively.

Conclusion: This study shows a limited impact of the 2018 RMMs on oral retinoids utilisation patterns among females of child-bearing age in four European countries. Pregnancies still occur during retinoid use, and oral retinoids are still prescribed to pregnant women. Contraception and pregnancy testing information was limited in most databases. Regulators, policymakers, prescribers, and researchers must rethink implementation strategies to avoid any pregnancy becoming temporarily related to retinoid use.